Empagliflozin's Fuel Hypothesis: Not so Soon.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 27508868.
- Also identified by DOI 10.1016/j.cmet.2016.07.018.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The EMPA-REG OUTCOME trial (Zinman et al., 2015) established cardioprotective effects of empagliflozin in high-risk diabetic patients, but the underlying mechanisms remain elusive. A recent hypothesis proposed that increased ketone oxidation contributed to the effect, but several caveats indicate that the role of myocardial ketone oxidation is far from clear.
Medical subject headings
- Diabetes Mellitus
- Hypoglycemic Agents